Cart
sales@molnova.com
AEE-788
CAS No. 497839-62-0
AEE-788 ( AEE 788;AEE788;NVP-AEE 788 )
Catalog No. M14666 CAS No. 497839-62-0
A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | In Stock |
|
| 5MG | 58 | In Stock |
|
| 10MG | 95 | In Stock |
|
| 25MG | 178 | In Stock |
|
| 50MG | 309 | In Stock |
|
| 100MG | 464 | In Stock |
|
| 500MG | 1044 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAEE-788
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.
-
DescriptionA potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively; inhibits growth factor-induced EGFR and ErbB2 phosphorylation in cells with IC50 of 11 and 220 nM, respectively, demonstrates antiproliferative activity against a range of EGFR and ErbB2-overexpressing cell lines; shows antitumor and antiangiogenic activity in vivo.Brain Cancer Phase 2 Discontinued
-
SynonymsAEE 788;AEE788;NVP-AEE 788
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptorc-Abl;c-Fms;EGFR;FLT1;HER2/ErbB2
-
Research AreaCancer
-
IndicationBrain Cancer
Chemical Information
-
CAS Number497839-62-0
-
Formula Weight440.58
-
Molecular FormulaC27H32N6
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESC[C@@H](NC1=C2C(NC(C3=CC=C(CN4CCN(CC)CC4)C=C3)=C2)=NC=N1)C5=CC=CC=C5
-
Chemical Name7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Traxler P, et al. Cancer Res. 2004 Jul 15;64(14):4931-41.
2. Goudar RK, et al. Mol Cancer Ther. 2005 Jan;4(1):101-12.
3. Park YW, et al. Clin Cancer Res. 2005 Mar 1;11(5):1963-73.
2. Goudar RK, et al. Mol Cancer Ther. 2005 Jan;4(1):101-12.
3. Park YW, et al. Clin Cancer Res. 2005 Mar 1;11(5):1963-73.
molnova catalog
related products
-
Gefitinib
A potent, selective, orally active EGFR inhibitor with IC50 of 23 nM; inhibits EGF-stimulated proliferation of KB cells with IC50 of 80 nM.
-
HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
-
WHI-P258
WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3.
